BioSpace News Archive

Business

Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more

New data for Genmab and AbbVie’s bispecific antibody Epkinly wowed analysts and could set the partners up for an expanded approval in diffuse large B cell lymphoma; deals have flowed steadily this week, including Novartis’ nearly $8 billion bet on mRNA drugs with China’s Abogen Biosciences; and could Sarepta Therapeutics turn things around from last year’s annus horribilis?

October 7, 2026

·

2 min read

·

Jef Akst

Press Releases

Boston Scientific appoints Joseph M. Fitzgerald Executive Vice President and Chief Operating Officer

October 7, 2026

·

5 min read

Press Releases

Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026

October 7, 2026

·

1 min read

Tension, separation, danger or risk concepts. Frayed rope is about to brake on blue background with copy space.

CAR-T

Doudna’s CAR T biotech Caribou to end R&D activities, slash staff as financing freezes up

Caribou Biosciences entered the scene in 2011 and went public in 2021. Over the course of its existence, the biotech has received funding and support from a handful of Big Pharma players, including Novartis, AbbVie and Pfizer.

October 7, 2026

·

3 min read

·

Tristan Manalac

Press Releases

Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

October 7, 2026

·

2 min read

Press Releases

CHARM Therapeutics announces first patient dosed and first cohort fully enrolled in its Phase I/II clinical trial of CHM-029 for Acute Myeloid Leukemia